Guo Tianwei, Wang Hongyue, Wu Fujian, Lu Wenjing, Zhu Min, Ma Shuhong, Zhang Yongshuai, Yan Yuting, Zhou Meng, Talanaite Didaer, Liu Siyu, Qi Man, Lan Feng, Liu Xujie
Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College/National Center for Cardiovascular Diseases, No. 167 Beilishi Road Xicheng District, Beijing, 100037, China.
Beijing Laboratory for Cardiovascular Precision Medicine, The Key Laboratory of Biomedical Engineering for Cardiovascular Disease Research, Ministry of Education, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China.
Stem Cell Res Ther. 2025 May 9;16(1):234. doi: 10.1186/s13287-025-04323-4.
Junctophilin-2 (JPH2) is a vital protein in cardiomyocytes, anchoring T-tubule and sarcoplasmic reticulum membranes to facilitate excitation-contraction coupling, a process essential for cardiac contractile function. Dysfunction of JPH2 is associated with cardiac disorders such as heart failure; however, prior studies using mouse models or primary human cardiomyocytes are limited by interspecies differences or poor cell viability, respectively. This study aimed to investigate JPH2's role in human cardiac function and disease using a novel stem cell-derived model, while introducing a new indicator to evaluate related cardiac impairments.
We generated a JPH2-knockout model using human embryonic stem cell-derived cardiomyocytes (hESC-CMs) with CRISPR/Cas9. Cellular morphology, contractile function, calcium dynamics, and electrophysiological properties were assessed via transmission electron microscopy, the CardioExcyte96 system, calcium imaging with Fluo-4 AM, and multi-electrode array recordings, respectively. Wild-type JPH2 was overexpressed through lentiviral transfection to evaluate rescue effects, and two JPH2 variants-one benign (G505S) and one pathogenic (E85K)-were introduced to study mutation-specific effects.
JPH2 knockout disrupted excitation-contraction coupling in hESC-CMs by impairing junctional membrane complex structure, leading to heart failure-like phenotypes with reduced contractility, altered calcium dynamics, and electrophysiological irregularities. Overexpression of wild-type JPH2 restored these functions, affirming its critical role in cardiac physiology. We identified excitation-contraction coupling delay (ECCD) as a novel indicator that precisely quantified coupling impairment severity, with its applicability validated across distinct JPH2 variants (G505S and E85K).
This study demonstrates JPH2's essential role in sustaining excitation-contraction coupling by stabilizing the junctional membrane complex, with its deficiency driving heart failure-like cardiac dysfunction. ECCD is established as a sensitive, comprehensive indicator for assessing JPH2-related impairment severity. These findings advance our understanding of JPH2 in cardiac pathology and position ECCD as a valuable tool for research and potential clinical evaluation, with JPH2 and calcium regulation emerging as promising therapeutic targets.
连接蛋白2(JPH2)是心肌细胞中的一种重要蛋白质,它锚定横小管和肌浆网膜以促进兴奋 - 收缩偶联,这是心脏收缩功能所必需的过程。JPH2功能障碍与心力衰竭等心脏疾病相关;然而,先前使用小鼠模型或原代人心肌细胞的研究分别受到种间差异或细胞活力差的限制。本研究旨在使用一种新型干细胞衍生模型研究JPH2在人类心脏功能和疾病中的作用,同时引入一种新的指标来评估相关的心脏损伤。
我们使用CRISPR/Cas9技术在人胚胎干细胞衍生的心肌细胞(hESC-CMs)中构建了JPH2基因敲除模型。分别通过透射电子显微镜、CardioExcyte96系统、Fluo-4 AM钙成像和多电极阵列记录评估细胞形态、收缩功能、钙动力学和电生理特性。通过慢病毒转染过表达野生型JPH2以评估挽救作用,并引入两个JPH2变体——一个良性变体(G505S)和一个致病变体(E85K)来研究突变特异性效应。
JPH2基因敲除通过损害连接膜复合体结构破坏了hESC-CMs中的兴奋 - 收缩偶联,导致心力衰竭样表型,收缩力降低、钙动力学改变和电生理异常。野生型JPH2的过表达恢复了这些功能,证实了其在心脏生理学中的关键作用。我们确定兴奋 - 收缩偶联延迟(ECCD)为一种新的指标,它能精确量化偶联损伤的严重程度,其适用性在不同的JPH2变体(G505S和E85K)中得到验证。
本研究证明JPH2通过稳定连接膜复合体在维持兴奋 - 收缩偶联中起关键作用,其缺陷导致心力衰竭样心脏功能障碍。ECCD被确立为评估JPH2相关损伤严重程度的敏感、综合指标。这些发现推进了我们对JPH2在心脏病理学中的理解,并将ECCD定位为研究和潜在临床评估的有价值工具,JPH2和钙调节成为有前景的治疗靶点。